Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Reviews |15 December 2009

Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II–Receptor Blockers for Ischemic Heart Disease Free

William L. Baker, PharmD; Craig I. Coleman, PharmD; Jeffrey Kluger, MD; Kurt M. Reinhart, PharmD; Ripple Talati, PharmD; Robert Quercia, MS; Olivia J. Phung, PharmD; C. Michael White, PharmD

William L. Baker, PharmD

Craig I. Coleman, PharmD

Jeffrey Kluger, MD

Kurt M. Reinhart, PharmD

Ripple Talati, PharmD

Robert Quercia, MS

Olivia J. Phung, PharmD

C. Michael White, PharmD

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
Disclaimer: The authors of this report are responsible for its content. Statements in the report should not be construed as endorsement by the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
Grant Support: By the University of Connecticut/Hartford Hospital Evidence-based Practice Center (contract 290-2007-10067-I) with the Agency for Healthcare Research and Quality.
Potential Conflicts of Interest: None disclosed.
Requests for Single Reprints: C. Michael White, PharmD, University of Connecticut/Hartford Hospital Evidence-based Practice Center, 80 Seymour Street, Hartford, CT 06102; e-mail, cmwhite@harthosp.org.
Current Author Addresses: Drs. Baker, Coleman, Kluger, Reinhart, Talati, Phung, and White and Mr. Quercia: University of Connecticut/Hartford Hospital Evidence-based Practice Center, 80 Seymour Street, Hartford, CT 06102-5037.
Author Contributions: Conception and design: W.L. Baker, C.I. Coleman, J. Kluger, K.M. Reinhart, C.M. White.
Analysis and interpretation of the data: W.L. Baker, C.I. Coleman, K.M. Reinhart, R. Quercia, C.M. White.
Drafting of the article: W.L. Baker, C.I. Coleman, K.M. Reinhart, R. Talati, C.M. White.
Critical revision of the article for important intellectual content: W.L. Baker, C.I. Coleman, J. Kluger, C.M. White.
Final approval of the article: W.L. Baker, C.I. Coleman, J. Kluger, K.M. Reinhart, R. Talati, R. Quercia, O.J. Phung, C.M. White.
Statistical expertise: W.L. Baker, C.I. Coleman.
Obtaining of funding: W.L. Baker, C.I. Coleman, C.M. White.
Administrative, technical, or logistic support: W.L. Baker, R. Talati, R. Quercia, O.J. Phung.
Collection and assembly of data: W.L. Baker, C.I. Coleman, K.M. Reinhart, R. Talati, O.J. Phung.
  • From the University of Connecticut/Hartford Hospital Evidence-based Practice Center, Hartford, Connecticut.
×
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
  • FULL ARTICLE
    • Abstract
    • Methods
    • Results
    • Discussion
      1. References
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link

Abstract

Background:

Patients with ischemic heart disease and preserved ventricular function experience considerable morbidity and mortality despite standard medical therapy.

Purpose:

To compare benefits and harms of using angiotensin-converting enzyme (ACE) inhibitors, angiotensin II–receptor blockers (ARBs), or combination therapy in adults with stable ischemic heart disease and preserved ventricular function.

Data Sources:

MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews (earliest date, July 2009) were searched without language restrictions.

Study Selection:

Two independent investigators screened citations for trials of at least 6 months' duration that compared ACE inhibitors, ARBs, or combination therapy with placebo or active control and reported any of several clinical outcomes.

Data Extraction:

Using standardized protocols, 2 independent investigators extracted information about study characteristics and rated the quality and strength of evidence. Disagreement was resolved by consensus.

Data Synthesis:

41 studies met eligibility criteria. Moderate- to high-strength evidence (7 trials; 32 559 participants) showed that ACE inhibitors reduce the relative risk (RR) for total mortality (RR, 0.87 [95% CI, 0.81 to 0.94]) and nonfatal myocardial infarction (RR, 0.83 [CI, 0.73 to 0.94]) but increase the RR for syncope (RR, 1.24 [CI, 1.02 to 1.52]) and cough (RR, 1.67 [CI, 1.22 to 2.29]) compared with placebo. Low-strength evidence (1 trial; 5926 participants) suggested that ARBs reduce the RR for the composite end point of cardiovascular mortality, nonfatal myocardial infarction, or stroke (RR, 0.88 [CI, 0.77 to 1.00]) but not for the individual components. Moderate-strength evidence (1 trial; 25 620 participants) showed similar effects on total mortality (RR, 1.07 [CI, 0.98 to 1.16]) and myocardial infarction (RR, 1.08 [CI, 0.94 to 1.23]) but an increased risk for discontinuations because of hypotension (P < 0.001) and syncope (P = 0.035) with combination therapy compared with ACE inhibitors alone.

Limitations:

Many studies either did not assess or did not report harms in a systematic manner. Many studies did not adequately report benefits or harms by various patient subgroups.

Conclusion:

Adding an ACE inhibitor to standard medical therapy improves outcomes, including reduced risk for mortality and myocardial infarctions, in some patients with stable ischemic heart disease and preserved ventricular function. Less evidence supports a benefit of ARB therapy, and combination therapy seems no better than ACE inhibitor therapy alone and increases harms.

Primary Funding Source:

Agency for Healthcare Research and Quality.

Editors' Notes

Context

  • Do patients already receiving standard therapy for ischemic heart disease benefit from additional treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II–receptor blockers (ARBs)?

Contribution

  • Authors of this systematic review concluded that ACE inhibitors reduce risk for mortality, stroke, and myocardial infarction in patients with stable ischemic heart disease and preserved left ventricular function who already receive standard treatments, such as β-blockers, statins, and aspirin. Evidence about effects of ARBs was scant. Combining ACE inhibitors and ARBs increased risks for hypotension and syncope compared with ACE inhibitor therapy alone.

—The Editors
An estimated 16 800 000 adults have ischemic heart disease (1). Standard medical therapy for these patients includes aspirin, β-blockers, and aggressive modification of risk factors (2, 3). Angiotensin-converting enzyme (ACE) inhibitors or angiotensin II–receptor blockers (ARBs) have established benefit in patients with heart failure and those who have had a myocardial infarction with ventricular dysfunction (4–11). Their use, however, in patients with preserved ventricular function is less certain.
Previous systematic reviews (12–17) have not included recent ACE inhibitor trials conducted in this population. In addition, no systematic review has evaluated ARB therapy or the combination of ACE inhibitor and ARB therapy in this population. The Agency for Healthcare Research and Quality commissioned this report (18) to review the evidence for the clinical effects and harms of using ACE inhibitors, ARBs, or combination therapy in adult patients with stable ischemic heart disease and preserved ventricular function receiving standard medical therapy.

Methods

We developed and followed a standard protocol for all steps of this review. A technical report that details methods, including literature search strategies and analysis plans, and includes evidence tables is available at www.effectivehealthcare.ahrq.gov(18). That report also includes information specific to patients who have recently had or will have a coronary revascularization procedure and to patients with an ischemic heart disease risk equivalent.

Key Questions

We refined key questions on the effectiveness of ACE inhibitors and ARBs in adults with stable ischemic heart disease and preserved ventricular function receiving standard medical therapy. We wrote these questions with input from a technical expert panel that included cardiologists, pharmacists, an internist, and a managed care organization representative. The following key questions were formulated.
1. In patients with stable ischemic heart disease who have preserved ventricular function, what are the benefits and harms of adding ACE inhibitors or ARBs to standard medical therapy compared with standard medical therapy alone?
2. In patients with stable ischemic heart disease who have preserved ventricular function and are receiving standard medical therapy, what are the benefits and harms of combining ACE inhibitors and ARBs compared with either an ACE inhibitor or an ARB alone?
3. What is the evidence that benefits or harms differ in prespecified subpopulations?

Data Sources and Searches

We searched MEDLINE (1966 to July 2009), EMBASE (1990 to July 2009) (19), and Cochrane Central Register of Controlled Trials (second quarter of 2009) (20) for both randomized, controlled trials (RCTs) and observational studies. We searched for systematic reviews in MEDLINE (1966 to July 2009) and the Cochrane Database of Systematic Reviews (second quarter of 2009) with no language restrictions. We also manually searched references from trials or reviews and major cardiology meeting abstracts (American Heart Association, American College of Cardiology, and European Society of Cardiology for June 2006 to July 2009). We ultimately did not include any studies that were published only in abstract form. We contacted authors of 11 trials to obtain information on their inclusion and exclusion criteria, including data on mean ejection fraction and inclusion of patients with heart failure, and received responses from 10. We also contacted authors from 4 trials for additional information about various clinical outcomes and were successful in getting additional information about such clinical outcomes as mortality (in 2 RCTs), myocardial infarction (in 3 RCTs), stroke (in 2 RCTs), and the composite of the 3 (in 3 RCTs).

Study Selection

Two independent reviewers assessed studies for inclusion in a parallel manner by using a priori–defined criteria. To assess potential benefits, we selected RCTs if they had 1) compared ACE inhibitor or ARB therapy with placebo or active control or compared combination ACE inhibitor and ARB therapy with either agent alone, 2) included patients with stable ischemic heart disease, 3) included patients with preserved left ventricular function (an average ejection fraction in experimental groups >0.40 or no systematic evaluation of left ventricular ejection fraction but exclusion of patients with signs or symptoms of heart failure), 4) included at least 75 patients, 5) followed patients for at least 6 months, and 6) reported data on at least 1 prespecified efficacy outcome (total mortality, cardiovascular mortality, nonfatal myocardial infarction, stroke, or a composite of the latter 3 end points).
We included RCTs in the harms evaluation if they satisfied criteria 1 to 5 above and reported data on a prespecified harm (including withdrawals due to adverse events, hypotension, syncope, or cough). We included observational studies if they met the first 3 criteria above, included at least 1000 patients, followed patients for at least 6 months, and reported data on a prespecified harm (withdrawals due to adverse events, hypotension, syncope, or cough).

Data Extraction and Quality Assessment

Two reviewers used a standardized data abstraction tool to independently extract study data. Data obtained from each study included interventions, study design, inclusion and exclusion criteria, methodological quality criteria, study population, patient baseline characteristics, use of concurrent standard medical therapies, benefits, and harms.
To ascertain the validity of eligible RCTs, 2 independent reviewers assessed the adequacy of randomization, concealment of allocation, blinding of patients, and use of intention-to-treat methodology. We used Evidence-based Practice Center methodology based on Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methods, to assess the strength of evidence. We used 4 required domains: risk for bias, consistency, directness, and precision (21). Evidence pertaining to each key question was classified into 3 broad categories: high, moderate, or low. Table 1 shows the results of this grading. The Assess the Methodological Quality of Systematic Review (AMSTAR) checklist was used to assess methodological quality of systematic reviews (22). We resolved disagreements about abstracted data, quality assessments, and ratings of evidence through discussion.

Table 1.

Outcomes, Strength of Evidence, and Conclusions

Table 1.

Data Synthesis and Analysis

We qualitatively examined data from all identified studies. We conducted meta-analyses when 2 or more RCTs adequate for pooling were available. We reported outcomes as pooled relative risks (RRs) with associated 95% CIs by using a random-effects model (23). We assessed statistical heterogeneity by using the I2 statistic (24). We evaluated the presence of publication bias and related biases by using funnel plots and Egger tests (25, 26), but the small number of studies limited the ability of these methods to detect publication bias (data not shown). We conducted an analysis comparing either an ACE inhibitor or an ARB with a control and then conducted analyses in which ACE inhibitor or ARB trials were evaluated separately.

Role of the Funding Source

This project was prepared by the University of Connecticut/Hartford Hospital Evidence-based Practice Center, Hartford, Connecticut, with funding from the Agency for Healthcare Research and Quality. The funding source formulated the initial study questions and provided copyright release for this manuscript, but did not participate in the literature search, data analysis, or interpretation of results.

Results

Results of Primary Literature Review

We screened 1531 abstracts and evaluated 366 full-text articles (Appendix Figure). A total of 44 articles (27–70), reporting on 9 RCTs (28, 31–33, 35, 37, 40–42) and 2 nonrandomized comparative studies (34, 36), as well as 6 systematic reviews (12–17) met our eligibility criteria.
Appendix Figure.
Literature search and selection.

IHD = ischemic heart disease; LV = left ventricular; RCT = randomized, controlled trial.

* We included 3 citations at this step after a manual reference search.

† We included 27 citations from the outcomes search and evaluated them for harms data.

‡ We included 1 citation at this step after a manual reference search.

Evidence of Benefits With ACE Inhibitors or ARBs

Eight RCTs (37 148 participants) met our inclusion criteria (Appendix Table) (28, 31–33, 35, 37, 40, 41). All of the RCTs were placebo-controlled (28, 31–33, 35, 37, 40, 41), and 1 also had an active comparator group (amlodipine) (35). All but 1 RCT (33) had adequate randomization, double blinding, and intention-to-treat methods. Seven of the RCTs evaluated ACE inhibitors, with 2 using enalapril (32, 35); 2 using ramipril (28, 31); and 1 each using perindopril (33), trandolapril (37), and zofenopril (40). We identified a single RCT that evaluated the ARB telmisartan (41) in patients with a history of intolerance to ACE inhibitors.

Appendix Table.

Description of Included RCTs

Appendix Table.
The mean age of the trial participants ranged from 57 to 67 years; 57% to 89% of participants were men. In all, 8% to 39% of participants had diabetes, 27% to 100% had hypertension, 7% to 45% had peripheral vascular disease, and 3% to 22% had a previous stroke or transient ischemic attack. Baseline medical therapy use also varied between trials. β-Blocker, antiplatelet, and lipid-lowering therapies were used in 10% to 79%, 3% to 95%, and 28% to 84% of patients in these studies, respectively. Differences between use of baseline therapy may have been related to the standard of care at the time the study was conducted or to underlying medical conditions of the patient population.

Total and Cardiovascular Mortality

Seven RCTs reported data on total mortality (28, 31–33, 35, 37, 41). Pooled analysis showed that ACE inhibitors reduced the risk for total mortality (RR, 0.87 [95% CI, 0.81 to 0.94]; I2 = 0%) compared with placebo. A single RCT that included patients intolerant to ACE inhibitors suggested that ARBs did not affect risk for total mortality compared with placebo (RR, 1.05 [CI, 0.91 to 1.20]) (41). The pooled RR that included the ACE inhibitor trials and the single ARB trial was 0.91 (CI, 0.84 to 0.98; I2 = 21.5%) (Figure).
Figure.
Meta-analysis of randomized, placebo-controlled trials of ACE inhibitors or ARBs in patients with stable ischemic heart disease and preserved left ventricular systolic function.

ACE = angiotensin-converting enzyme; ARB = angiotensin II–receptor blocker; CAMELOT = Comparison of Amlodipine vs. Enalapril to Limit Occurrences of Thrombosis; EUROPA = European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease; HOPE = Heart Outcomes Prevention Evaluation; MI = myocardial infarction; PART-2 = Prevention of Atherosclerosis with Ramipril 2; PEACE = Prevention of Events with Angiotensin Converting Enzyme Inhibition; RR = relative risk; SCAT = Simvastatin/Enalapril Coronary Atherosclerosis Trial; TRANSCEND = Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease.

Six RCTs reported data on cardiovascular mortality (28–31, 33, 35, 37, 41). Pooled analysis showed that ACE inhibitors compared with placebo reduced the risk for cardiovascular mortality (RR, 0.83 [CI, 0.70 to 0.98]; I2 = 45.5%). A single RCT suggested that ARBs did not affect risk for cardiovascular mortality compared with placebo (RR, 1.02 [CI, 0.86 to 1.22]). The pooled RR that included the ACE inhibitor trials and the single ARB trial was 0.87 (CI, 0.75 to 1.02; I2 = 57.9%) (Figure). The pooled result and CI are suggestive of and compatible with a reduced risk for cardiovascular mortality. The heterogeneity is caused, in part, by the inclusion of the ARB trial and 1 ACE inhibitor trial (35), which suggested an increased risk for events with ACE inhibitor use. The increased baseline use of antiplatelet agents, shorter follow-up, and decreased intensity of ACE inhibition in that trial versus other ACE inhibitor trials may explain the findings.

Nonfatal Myocardial Infarction

Six RCTs evaluating ACE inhibitors reported data on nonfatal myocardial infarction (28–33, 35, 37). All but 1 RCT (33) had adequate randomization, double blinding, and intention-to-treat methods. Pooled analysis demonstrated that ACE inhibitors reduced the risk for nonfatal myocardial infarction (RR, 0.83 [CI, 0.73 to 0.94]; I2 = 30.5%) compared with placebo (Figure). Two of the RCTs (33, 35) with small sample sizes and low event rates showed more dramatic reductions in the risk for nonfatal myocardial infarction than the others, but the CIs were very large and overlapped with the pooled estimate.

Stroke

Seven RCTs reported data on stroke (28–33, 35, 37, 41). Pooled analysis showed that ACE inhibitors reduced the risk for stroke (RR, 0.78 [CI, 0.63 to 0.97]; I2 = 37.7%) compared with placebo. The pooled RR in the single ARB trial was 0.83 (CI, 0.65 to 1.06), which suggests and is compatible with a reduced risk for stroke. The pooled RR estimate that included the ACE inhibitor trials and the single ARB trial was 0.79 (CI, 0.67 to 0.93; I2 = 27.6%) (Figure). One RCT (31), which used a different event definition (nonfatal stroke requiring hospital admission), suggested that patients receiving ACE inhibitors had an increased risk for stroke compared with those receiving placebo. Another RCT (32) showed that ACE inhibitors compared with placebo decreased risk for stroke more than that reported in other trials. Both trials had a small sample size and event rate, which resulted in CIs that overlapped with the pooled estimate.

Composite End Point

Three RCTs (28, 37, 41) reported data on the composite end point (cardiovascular mortality, nonfatal myocardial infarction, or stroke). Pooled analysis of 2 RCTs (28, 37) suggested that ACE inhibitors reduced the risk for the composite end point (RR, 0.85 [CI, 0.72 to 1.01]) compared with placebo. The single ARB trial also suggested a reduced risk (RR, 0.88 [CI, 0.77 to 1.00]). The pooled RR that included the ACE inhibitor trials and the single ARB trial was 0.86 (CI, 0.77 to 0.95; I2 = 58.0%), probably due to increased power (Figure).

Evidence of Harms With ACE Inhibitors or ARBs

Withdrawals Due to Adverse Events

Three of 8 RCTs (31, 35, 37) reported data on withdrawals due to adverse events, all evaluating ACE inhibitors (Table 2). Pooled analysis of these selected reports suggested that patients receiving ACE inhibitors were more likely than those receiving placebo to withdraw because of adverse events (RR, 2.30 [CI, 1.34 to 3.95]; I2 = 87.2%). One study (31) showed a more than 10-fold increase in the risk for withdrawals (RR, 10.37 [CI, 3.42 to 31.72]), whereas another study (37) showed a slightly more than 2-fold increase (RR, 2.21 [CI, 1.93 to 2.54]).

Table 2.

Harms Event Rates for ACE Inhibitors

Table 2.

Hypotension

Three of 8 trials (28, 35, 40) reported data on hypotension, all evaluating ACE inhibitors (Table 2). One study (28) reported only serious adverse events and therefore reported a decreased rate, whereas another study (35) reported a higher rate of hypotension (9.5% in the ACE inhibitor group) than other studies (0.04% to 1.2% in the ACE inhibitor group) (28, 40). Pooled analysis showed no overall effect of ACE inhibitors on hypotension risk (RR, 1.79 [CI, 0.68 to 4.71]; I2 = 40.6%), although the CI was wide and the analysis was probably underpowered.

Syncope

Two of 8 trials (28, 37) reported data on syncope, both evaluating ACE inhibitors (Table 2). One trial (28) reported syncope as a serious adverse event, resulting in a low risk for syncope (0.04%) compared with the other trial (4.4%) (37). Pooled analysis showed that ACE inhibitors increased the risk for syncope (RR, 1.24 [CI, 1.02 to 1.52]) compared with placebo.

Cough

Three of 8 trials (28, 35, 37) reported data on cough, all evaluating ACE inhibitors (Table 2). The overall incidence of cough varied widely between trials, with 1 trial (27) reporting only serious events and thus a decreased overall rate (0.3%). The other 2 trials (35, 37) reported rates of cough of 9.2% and 33.3%. Pooled analysis showed an increased risk for cough with ACE inhibitors (RR, 1.67 [CI, 1.22 to 2.29]; I2 = 60.2%) compared with placebo.

Evidence of Benefits and Harms With a Combination of ACE Inhibitors and ARBs

We found 1 trial (42) of combination therapy in this population. The ONTARGET (Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) investigators randomly assigned 25 620 patients with vascular disease or high-risk diabetes to 1 of 3 therapies (ramipril, telmisartan, or combination of the 2 drugs) for a mean of 4.5 years (42). Total mortality (RR, 1.07 [CI, 0.98 to 1.16]), cardiovascular mortality (RR, 1.04 [CI, 0.93 to 1.17]), total myocardial infarctions (RR, 1.08 [CI, 0.94 to 1.23]), stroke (RR, 0.93 [CI, 0.81 to 1.07]), or the composite of the latter 3 end points (RR, 1.00 [CI, 0.93 to 1.09]) did not significantly differ between combination therapy and ramipril alone. Combination therapy, however, was associated with more study discontinuations (P < 0.001), as well as discontinuations due to hypotension (P < 0.001) and syncope (P = 0.03), compared with ramipril alone.
The ONTARGET investigators also evaluated the comparative effectiveness of an ACE inhibitor with that of an ARB. No differences were found in any aforementioned end points when ACE inhibitor and ARB therapy were directly compared. However, ARB therapy did result in fewer study discontinuations (P = 0.02) and discontinuations due to hypotension (P < 0.001) and cough (P < 0.001) than did ACE inhibitor therapy (42).

Evidence of Benefits and Harms, by Subpopulation

We found few trials that evaluated the comparative benefits or harms of ACE inhibitors, ARBs, or their combination in various patient subgroups. A pooled analysis of 2 trials (28, 33) demonstrated that ACE inhibitors reduced event rates more in patients who did not receive antiplatelet therapy than in those who did receive it (P value for interaction < 0.003) (13). Angiotensin-converting enzyme inhibitors reduced event rates more in patients without previous coronary revascularization than in those with revascularization (P value for interaction = 0.078). No differential benefits resulting from ACE inhibitors were noted for those receiving or not receiving β-blockers (P value for interaction = 0.139) or lipid-lowering agents (P value for interaction = 0.651). A single RCT (41) found no difference in outcomes resulting from ARB therapy in patients either receiving or not receiving statins (P value for interaction = 0.287). Of the 4 RCTs (28, 35, 41, 42) that assessed the effect of baseline risk on treatment effects, only 1 (28) found a positive relationship on the risk for the composite end point.

Discussion

Moderate- to high-strength evidence demonstrates that ACE inhibitors reduce the RR for total mortality, cardiovascular mortality, nonfatal myocardial infarction, and stroke in adults with stable ischemic heart disease and preserved ventricular function (Table 1). This includes patients with a history of coronary artery, peripheral vascular, or cerebrovascular disease, as well as patients with diabetes and evidence of end-organ damage. Data are insufficient to adequately assess the benefits of ARBs, because only 1 high-quality RCT (41) was identified, and the population was limited to patients who could not tolerate ACE inhibitors. A single study with moderate-strength evidence showed similar effects on total mortality, cardiovascular mortality, myocardial infarction, and stroke with combination ACE inhibitor and ARB therapy compared with an ACE inhibitor alone but showed a greater risk for study discontinuations and discontinuations due to hypotension and syncope (42).
Most patients in the included trials were receiving concomitant antiplatelet and lipid-lowering therapy, with approximately half receiving β-blockers. We could not find differences in outcomes among patients receiving ACE inhibitors with or without β-blockers or lipid-lowering therapy (13). Some evidence suggests that ACE inhibitors confer more pronounced benefits in patients without concomitant antiplatelet therapy than in those who are receiving antiplatelet therapy (13). Whether this is related to a drug interaction between aspirin and ACE inhibitors (blocking the release of vasodilatory prostaglandins) or also occurs with adenosine diphosphate inhibitors is not known (71–75). The effect of antiplatelet therapy on ARB benefits is not known.
Study factors, including the use of different ACE inhibitors, varying doses of ACE inhibitors, differences in baseline blood pressure, and different degrees of blood pressure reduction, may affect pooled estimates of effect or heterogeneity (12, 14, 76, 77). Angiotensin-converting enzyme inhibitors considered to be tissue-specific (ramipril, quinapril, perindopril, or trandolapril) have not provided better cardioprotection than serum-specific agents (for example, enalapril) (76, 78–80). In addition, ACE inhibitors provide similar benefits regardless of changes in blood pressure or history of hypertension (12, 28, 33). However, using increased doses of ACE inhibitors may improve the ability to slow atherosclerosis (81), which may accentuate clinical benefits.
Our review has several limitations. We could analyze only data from published trials and data provided from trial authors. We could not adequately assess the possibility of publication bias for several outcomes, although selective reporting of both benefits and harms was possible. Subgroup data were inconsistently reported. Most studies evaluated patients between ages 60 and 67 years and predominantly enrolled men (57% to 89%), negatively affecting applicability. Few trials reported average left ventricular ejection fractions, and none of the trials assessed the affect of ventricular function on outcomes. Only 1 trial compared ARBs with placebo, and only 1 trial compared combination therapy with an ACE inhibitor alone. As a result, the ability to formally test for statistical heterogeneity was limited in many analyses, and the resultant strength of evidence reduced. Finally, data reporting on harms were inconsistent and incomplete, compromising our ability to determine the balance of benefits to harms.
In conclusion, adding an ACE inhibitor to standard medical therapy improves clinical outcomes in some patients with stable ischemic heart disease and preserved left ventricular function. Combination therapy seems no better than ACE inhibitor therapy alone and increases harms. Future trials are needed to more clearly define the role of ARBs in this patient population.

References

  1. Lloyd-Jones
    D
    ,  
    Adams
    R
    ,  
    Carnethon
    M
    ,  
    De Simone
    G
    ,  
    Ferguson
    TB
    ,  
    Flegal
    K
    .  et al. 
    American Heart Association Statistics Committee and Stroke Statistics Subcommittee
    Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.
    Circulation
    2009
    119
    21
    181
     PubMed
    CrossRef
  2. Gibbons
    RJ
    ,  
    Abrams
    J
    ,  
    Chatterjee
    K
    ,  
    Daley
    J
    ,  
    Deedwania
    PC
    ,  
    Douglas
    JS
    .  et al. 
    American College of Cardiology
    ACC/AHA 2002 guideline update for the management of patients with chronic stable angina—summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina).
    J Am Coll Cardiol
    2003
    41
    159
    68
     PubMed
  3. Fraker
    TD
    Jr
    ,  
    Fihn
    SD
    ,  
    2002 Chronic Stable Angina Writing Committee
    American College of Cardiology
    American Heart Association
    Gibbons
    RJ
    .  et al. 
    Chronic Stable Angina Writing Committee
    2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina.
    J Am Coll Cardiol
    2007
    50
    2264
    74
     PubMed
  4. Ambrosioni
    E
    ,  
    Borghi
    C
    ,  
    Magnani
    B
    .  
    the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators
    The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction.
    N Engl J Med
    1995
    332
    80
    5
     PubMed
  5. Køber
    L
    ,  
    Torp-Pedersen
    C
    ,  
    Carlsen
    JE
    ,  
    Bagger
    H
    ,  
    Eliasen
    P
    ,  
    Lyngborg
    K
    .  et al. 
    Trandolapril Cardiac Evaluation (TRACE) Study Group
    A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction.
    N Engl J Med
    1995
    333
    1670
    6
     PubMed
  6. Garg
    R
    ,  
    Yusuf
    S
    .  
    Collaborative Group on ACE Inhibitor Trials
    Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure.
    JAMA
    1995
    273
    1450
    6
     PubMed
  7. Pitt
    B
    ,  
    Poole-Wilson
    PA
    ,  
    Segal
    R
    ,  
    Martinez
    FA
    ,  
    Dickstein
    K
    ,  
    Camm
    AJ
    .  et al. 
    Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II.
    Lancet
    2000
    355
    1582
    7
     PubMed
  8. Cohn
    JN
    ,  
    Tognoni
    G
    .  
    Valsartan Heart Failure Trial Investigators
    A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    N Engl J Med
    2001
    345
    1667
    75
     PubMed
  9. Pfeffer
    MA
    ,  
    Swedberg
    K
    ,  
    Granger
    CB
    ,  
    Held
    P
    ,  
    McMurray
    JJ
    ,  
    Michelson
    EL
    .  et al. 
    CHARM Investigators and Committees
    Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.
    Lancet
    2003
    362
    759
    66
     PubMed
  10. McMurray
    JJ
    ,  
    Ostergren
    J
    ,  
    Swedberg
    K
    ,  
    Granger
    CB
    ,  
    Held
    P
    ,  
    Michelson
    EL
    .  et al. 
    CHARM Investigators and Committees
    Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
    Lancet
    2003
    362
    767
    71
     PubMed
  11. Pfeffer
    MA
    ,  
    McMurray
    JJ
    ,  
    Velazquez
    EJ
    ,  
    Rouleau
    JL
    ,  
    Køber
    L
    ,  
    Maggioni
    AP
    .  et al. 
    Valsartan in Acute Myocardial Infarction Trial Investigators
    Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
    N Engl J Med
    2003
    349
    1893
    906
     PubMed
  12. Al-Mallah
    MH
    ,  
    Tleyjeh
    IM
    ,  
    Abdel-Latif
    AA
    ,  
    Weaver
    WD
    .  
    Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials.
    J Am Coll Cardiol
    2006
    47
    1576
    83
     PubMed
  13. Dagenais
    GR
    ,  
    Pogue
    J
    ,  
    Fox
    K
    ,  
    Simoons
    ML
    ,  
    Yusuf
    S
    .  
    Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials.
    Lancet
    2006
    368
    581
    8
     PubMed
  14. Danchin
    N
    ,  
    Cucherat
    M
    ,  
    Thuillez
    C
    ,  
    Durand
    E
    ,  
    Kadri
    Z
    ,  
    Steg
    PG
    .  
    Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
    Arch Intern Med
    2006
    166
    787
    96
     PubMed
  15. Saha
    SA
    ,  
    Molnar
    J
    ,  
    Arora
    RR
    .  
    Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials.
    J Cardiovasc Pharmacol Ther
    2007
    12
    192
    204
     PubMed
  16. Lang
    CD
    ,  
    Arora
    RR
    ,  
    Saha
    SA
    ,  
    Molnar
    J
    .  
    Bayesian meta-analysis of tissue angiotensin-converting enzyme inhibitors for reduction of adverse cardiovascular events in patients with diabetes mellitus and preserved left ventricular function.
    J Cardiometab Syndr
    2008
    3
    45
    52
     PubMed
  17. Saha
    SA
    ,  
    Molnar
    J
    ,  
    Arora
    RR
    .  
    Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Diabetes Obes Metab
    2008
    10
    41
    52
     PubMed
  18. www.effectivehealthcare.ahrq.gov
    Coleman
    CI
    ,  
    Baker
    WL
    ,  
    Kluger
    J
    ,  
    Reinhart
    K
    ,  
    Talati
    R
    ,  
    Quercia
    R
    .  et al. 
    Comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease. Comparative Effectiveness Review no. 18. (Prepared by University of Connecticut/Hartford Hospital Evidence-based Practice Center under contract no. 290-2007-10067-I.)
    Rockville, MD
    Agency for Healthcare Research and Quality
    2009
  19. Wong
    SS
    ,  
    Wilczynski
    NL
    ,  
    Haynes
    RB
    .  
    Comparison of top-performing search strategies for detecting clinically sound treatment studies and systematic reviews in MEDLINE and EMBASE.
    J Med Libr Assoc
    2006
    94
    451
    5
     PubMed
  20. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.1 (updated September 2008). The Cochrane Collaboration; 2008. Accessed atwww.cochrane-handbook.orgon 7 October 2009.
  21. Schunemann H, Brozek J, Oxman A, eds. GRADE handbook for grading quality of evidence and strength of recommendation. Version 3.2 (updated March 2008). The GRADE Working Group; 2008. Accessed atwww.gradeworkinggroup.orgon 13 October 2009.
  22. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007;7:10. [PMID: 17302989]
  23. DerSimonian
    R
    ,  
    Laird
    N
    .  
    Meta-analysis in clinical trials.
    Control Clin Trials
    1986
    7
    177
    88
     PubMed
  24. Higgins
    JP
    ,  
    Thompson
    SG
    ,  
    Deeks
    JJ
    ,  
    Altman
    DG
    .  
    Measuring inconsistency in meta-analyses.
    BMJ
    2003
    327
    557
    60
     PubMed
  25. Bax
    L
    ,  
    Yu
    LM
    ,  
    Ikeda
    N
    ,  
    Tsuruta
    H
    ,  
    Moons
    KG
    .  
    Development and validation of MIX: comprehensive free software for meta-analysis of causal research data.
    BMC Med Res Methodol
    2006
    6
    50
     PubMed
  26. Egger
    M
    ,  
    Davey Smith
    G
    ,  
    Schneider
    M
    ,  
    Minder
    C
    .  
    Bias in meta-analysis detected by a simple, graphical test.
    BMJ
    1997
    315
    629
    34
     PubMed
  27. Duval
    S
    ,  
    Tweedie
    R
    .  
    Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis.
    Biometrics
    2000
    56
    455
    63
     PubMed
  28. Yusuf
    S
    ,  
    Sleight
    P
    ,  
    Pogue
    J
    ,  
    Bosch
    J
    ,  
    Davies
    R
    ,  
    Dagenais
    G
    .  
    The Heart Outcomes Prevention Evaluation Study Investigators
    Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
    N Engl J Med
    2000
    342
    145
    53
     PubMed
  29. Dagenais
    GR
    ,  
    Yusuf
    S
    ,  
    Bourassa
    MG
    ,  
    Yi
    Q
    ,  
    Bosch
    J
    ,  
    Lonn
    EM
    .  et al. 
    HOPE Investigators
    Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study.
    Circulation
    2001
    104
    522
    6
     PubMed
  30. Salehian
    O
    ,  
    Healey
    J
    ,  
    Stambler
    B
    ,  
    Alnemer
    K
    ,  
    Almerri
    K
    ,  
    Grover
    J
    .  et al. 
    HOPE Investigators
    Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study.
    Am Heart J
    2007
    154
    448
    53
     PubMed
  31. MacMahon
    S
    ,  
    Sharpe
    N
    ,  
    Gamble
    G
    ,  
    Clague
    A
    ,  
    Mhurchu
    CN
    ,  
    Clark
    T
    .  et al. 
    Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril.
    J Am Coll Cardiol
    2000
    36
    438
    43
     PubMed
  32. Teo
    KK
    ,  
    Burton
    JR
    ,  
    Buller
    CE
    ,  
    Plante
    S
    ,  
    Catellier
    D
    ,  
    Tymchak
    W
    .  et al. 
    Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT).
    Circulation
    2000
    102
    1748
    54
     PubMed
  33. Fox
    KM
    .  
    EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators
    Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).
    Lancet
    2003
    362
    782
    8
     PubMed
  34. Kondo
    J
    ,  
    Sone
    T
    ,  
    Tsuboi
    H
    ,  
    Mukawa
    H
    ,  
    Morishima
    I
    ,  
    Uesugi
    M
    .  et al. 
    Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease.
    Am Heart J
    2003
    146
    20
     PubMed
  35. Nissen
    SE
    ,  
    Tuzcu
    EM
    ,  
    Libby
    P
    ,  
    Thompson
    PD
    ,  
    Ghali
    M
    ,  
    Garza
    D
    .  et al. 
    CAMELOT Investigators
    Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial.
    JAMA
    2004
    292
    2217
    25
     PubMed
  36. Yui
    Y
    ,  
    Sumiyoshi
    T
    ,  
    Kodama
    K
    ,  
    Hirayama
    A
    ,  
    Nonogi
    H
    ,  
    Kanmatsuse
    K
    .  et al. 
    Japan Multicenter Investigation for Cardiovascular Diseases-B Study Group
    Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial.
    Hypertens Res
    2004
    27
    181
    91
     PubMed
  37. Braunwald
    E
    ,  
    Domanski
    MJ
    ,  
    Fowler
    SE
    ,  
    Geller
    NL
    ,  
    Gersh
    BJ
    ,  
    Hsia
    J
    .  et al. 
    PEACE Trial Investigators
    Angiotensin-converting-enzyme inhibition in stable coronary artery disease.
    N Engl J Med
    2004
    351
    2058
    68
     PubMed
  38. Zannad
    F
    ,  
    Kessler
    M
    ,  
    Lehert
    P
    ,  
    Grünfeld
    JP
    ,  
    Thuilliez
    C
    ,  
    Leizorovicz
    A
    .  et al. 
    Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies.
    Kidney Int
    2006
    70
    1318
    24
     PubMed
  39. Takahashi
    A
    ,  
    Takase
    H
    ,  
    Toriyama
    T
    ,  
    Sugiura
    T
    ,  
    Kurita
    Y
    ,  
    Ueda
    R
    .  et al. 
    Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis—a randomized study.
    Nephrol Dial Transplant
    2006
    21
    2507
    12
     PubMed
  40. Borghi
    C
    ,  
    Ambrosioni
    E
    .  
    Survival of Myocardial Infarction Long-term Evaluation Study Group
    Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study.
    Am Heart J
    2007
    153
     PubMed
  41. Yusuf
    S
    ,  
    Teo
    K
    ,  
    Anderson
    C
    ,  
    Pogue
    J
    ,  
    Dyal
    L
    ,  
    Copland
    I
    .  et al. 
    Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators
    Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.
    Lancet
    2008
    372
    1174
    83
     PubMed
  42. Yusuf
    S
    ,  
    Teo
    KK
    ,  
    Pogue
    J
    ,  
    Dyal
    L
    ,  
    Copland
    I
    ,  
    Schumacher
    H
    .  et al. 
    ONTARGET Investigators
    Telmisartan, ramipril, or both in patients at high risk for vascular events.
    N Engl J Med
    2008
    358
    1547
    59
     PubMed
  43. The HOPE Study Investigators
    The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events.
    Can J Cardiol
    1996
    12
    127
    37
     PubMed
  44. Pfeffer
    MA
    ,  
    Domanski
    M
    ,  
    Rosenberg
    Y
    ,  
    Verter
    J
    ,  
    Geller
    N
    ,  
    Albert
    P
    .  et al. 
    Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition.
    Am J Cardiol
    1998
    82
    25H
    30H
     PubMed
  45. Zannad
    F
    ,  
    Kessler
    M
    ,  
    Grünfeld
    JP
    ,  
    Thuilliez
    C
    .  
    FOSInopril in DIALysis Investigators
    FOSIDIAL: a randomised placebo controlled trial of the effects of fosinopril on cardiovascular morbidity and mortality in haemodialysis patients. Study design and patients' baseline characteristics.
    Fundam Clin Pharmacol
    2002
    16
    353
    60
     PubMed
  46. Teo
    KK
    ,  
    Burton
    JR
    ,  
    Buller
    C
    ,  
    Plante
    S
    ,  
    Yokoyama
    S
    ,  
    Montague
    TJ
    .  
    Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). SCAT Investigators.
    Can J Cardiol
    1997
    13
    591
    9
     PubMed
  47. Topouchian
    J
    ,  
    El Feghali
    R
    ,  
    Pannier
    B
    ,  
    Wang
    S
    ,  
    Zhao
    F
    ,  
    Smetana
    K
    .  et al. 
    Arterial stiffness and pharmacological interventions—the TRanscend arterial stiffNess Substudy (TRANS study).
    Vasc Health Risk Manag
    2007
    3
    381
    7
     PubMed
  48. Fox
    KM
    ,  
    Henderson
    JR
    ,  
    Bertrand
    ME
    ,  
    Ferrari
    R
    ,  
    Remme
    WJ
    ,  
    Simoons
    ML
    .  
    The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA).
    Eur Heart J
    1998
    19
    Suppl J
    J52
    5
     PubMed
  49. Gomma
    AH
    ,  
    Fox
    KM
    .  
    The EUROPA trial: design, baseline demography and status of the substudies.
    Cardiovasc Drugs Ther
    2001
    15
    169
    79
     PubMed
  50. Simoons
    ML
    ,  
    Vos
    J
    ,  
    de Feyter
    PJ
    ,  
    Bots
    ML
    ,  
    Remme
    WJ
    ,  
    Grobbee
    DE
    .  et al. 
    EUROPA substudies, confirmation of pathophysiological concepts. European trial on reduction of cardiac events with perindopril in stable coronary artery disease.
    Eur Heart J
    1998
    19
    Suppl J
    J56
    60
     PubMed
  51. Kjøller-Hansen
    L
    ,  
    Steffensen
    R
    ,  
    Grande
    P
    .  
    The Angiotensin Converting Enzyme Inhibition Post Revascularization Study (APRES). Effects of ramipril in patients with reduced left ventricular function. Rationale, design, methods, baseline characteristics and first-year experience.
    Scand Cardiovasc J
    1998
    32
    225
    32
     PubMed
  52. Teo
    K
    ,  
    Yusuf
    S
    ,  
    Sleight
    P
    ,  
    Anderson
    C
    ,  
    Mookadam
    F
    ,  
    Ramos
    B
    .  et al. 
    ONTARGET/TRANSCEND Investigators
    Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
    Am Heart J
    2004
    148
    52
    61
     PubMed
  53. Unger
    T
    .  
    The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.
    Am J Cardiol
    2003
    91
    28G
    34G
     PubMed
  54. Mancia
    G
    ,  
    Jakobsen
    A
    ,  
    Heroys
    J
    ,  
    Ralph
    A
    ,  
    Rees
    T
    ,  
    Shaw
    M
    .  
    Cardiac and vascular protection: the potential of ONTARGET.
    Medscape J Med
    2008
    10
    Suppl
    S7
     PubMed
  55. Heart Outcomes Prevention Evaluation Study Investigators
    Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy.
    Lancet
    2000
    355
    253
    9
     PubMed
  56. Daly
    CA
    ,  
    Fox
    KM
    ,  
    Remme
    WJ
    ,  
    Bertrand
    ME
    ,  
    Ferrari
    R
    ,  
    Simoons
    ML
    .  
    EUROPA Investigators
    The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy.
    Eur Heart J
    2005
    26
    1369
    78
     PubMed
  57. Yui
    Y
    ,  
    Sumiyoshi
    T
    ,  
    Kodama
    K
    ,  
    Hirayama
    A
    ,  
    Nonogi
    H
    ,  
    Kanmatsuse
    K
    .  et al. 
    Nifedipine retard was as effective as angiotensin converting enzyme inhibitors in preventing cardiac events in high-risk hypertensive patients with diabetes and coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) subgroup analysis.
    Hypertens Res
    2004
    27
    449
    56
     PubMed
  58. Solomon
    SD
    ,  
    Rice
    MM
    ,  
    A Jablonski
    K
    ,  
    Jose
    P
    ,  
    Domanski
    M
    ,  
    Sabatine
    M
    .  et al. 
    Prevention of Events with ACE inhibition (PEACE) Investigators
    Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial.
    Circulation
    2006
    114
    26
    31
     PubMed
  59. Brugts
    JJ
    ,  
    Boersma
    E
    ,  
    Chonchol
    M
    ,  
    Deckers
    JW
    ,  
    Bertrand
    M
    ,  
    Remme
    WJ
    .  et al. 
    EUROPA Investigators
    The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial.
    J Am Coll Cardiol
    2007
    50
    2148
    55
     PubMed
  60. Mann
    JF
    ,  
    Gerstein
    HC
    ,  
    Pogue
    J
    ,  
    Bosch
    J
    ,  
    Yusuf
    S
    .  
    Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.
    Ann Intern Med
    2001
    134
    629
    36
     PubMed
  61. Yui
    Y
    ,  
    Shinoda
    E
    ,  
    Kodama
    K
    ,  
    Hirayama
    A
    ,  
    Nonogi
    H
    ,  
    Haze
    K
    .  et al. 
    Japan Multicenter Investigation for Cardiovascular Diseases B (JMIC-B) Study Group
    Nifedipine retard prevents hospitalization for angina pectoris better than angiotensin-converting enzyme inhibitors in hypertensive Japanese patients with previous myocardial infarction (JMIC-B substudy).
    J Hypertens
    2007
    25
    2019
    26
     PubMed
  62. Bertrand
    ME
    ,  
    Remme
    WJ
    ,  
    Fox
    KM
    ,  
    Ferrari
    R
    ,  
    Simoons
    ML
    .  
    EUROPA Investigators
    Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.
    Int J Cardiol
    2007
    121
    57
    61
     PubMed
  63. Gianni
    M
    ,  
    Bosch
    J
    ,  
    Pogue
    J
    ,  
    Probstfield
    J
    ,  
    Dagenais
    G
    ,  
    Yusuf
    S
    .  et al. 
    Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients.
    Eur Heart J
    2007
    28
    1382
    8
     PubMed
  64. Deckers
    JW
    ,  
    Goedhart
    DM
    ,  
    Boersma
    E
    ,  
    Briggs
    A
    ,  
    Bertrand
    M
    ,  
    Ferrari
    R
    .  et al. 
    Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk.
    Eur Heart J
    2006
    27
    796
    801
     PubMed
  65. Fox
    KM
    ,  
    Bertrand
    ME
    ,  
    Remme
    WJ
    ,  
    Ferrari
    R
    ,  
    Simoons
    ML
    ,  
    Deckers
    JW
    .  
    EUROPA Investigators
    Efficacy of perindopril in reducing risk of cardiac events in patients with revascularized coronary artery disease.
    Am Heart J
    2007
    153
    629
    35
     PubMed
  66. Mann
    JF
    ,  
    Yi
    QL
    ,  
    Sleight
    P
    ,  
    Dagenais
    GR
    ,  
    Gerstein
    HC
    ,  
    Lonn
    EM
    .  et al. 
    HOPE Investigators
    Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study.
    Clin Nephrol
    2005
    63
    181
    7
     PubMed
  67. Gerstein
    HC
    ,  
    Bosch
    J
    ,  
    Pogue
    J
    ,  
    Taylor
    DW
    ,  
    Zinman
    B
    ,  
    Yusuf
    S
    .  
    Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation.
    Diabetes Care
    1996
    19
    1225
    8
     PubMed
  68. HOPE/HOPE-TOO Study Investigators
    Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension.
    Circulation
    2005
    112
    1339
    46
     PubMed
  69. Bertrand
    ME
    ,  
    Fox
    KM
    ,  
    Remme
    WJ
    ,  
    Ferrari
    R
    ,  
    Simoons
    ML
    .  
    Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: a subgroup analysis of the EUROPA trial.
    Arch Cardiovasc Dis
    2009
    102
    89
    96
     PubMed
  70. Remme
    WJ
    ,  
    Deckers
    JW
    ,  
    Fox
    KM
    ,  
    Ferrari
    R
    ,  
    Bertrand
    M
    ,  
    Simoons
    ML
    .  
    EUROPA Investigators
    Secondary prevention of coronary disease with ACE inhibition—does blood pressure reduction with perindopril explain the benefits in EUROPA?
    Cardiovasc Drugs Ther
    2009
    23
    161
    70
     PubMed
  71. Rosendorff
    C
    ,  
    Black
    HR
    ,  
    Cannon
    CP
    ,  
    Gersh
    BJ
    ,  
    Gore
    J
    ,  
    Izzo
    JL
    Jr
    .  et al. 
    American Heart Association Council for High Blood Pressure Research
    Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention.
    Circulation
    2007
    115
    2761
    88
     PubMed
  72. Brunner-La Rocca
    HP
    .  
    Interaction of angiotensin-converting enzyme inhibition and aspirin in congestive heart failure: long controversy finally resolved? [Editorial].
    Chest
    2003
    124
    1192
    4
     PubMed
  73. Townend
    JN
    ,  
    Doran
    J
    ,  
    Lote
    CJ
    ,  
    Davies
    MK
    .  
    Peripheral haemodynamic effects of inhibition of prostaglandin synthesis in congestive heart failure and interactions with captopril.
    Br Heart J
    1995
    73
    434
    41
     PubMed
  74. Spaulding
    C
    ,  
    Charbonnier
    B
    ,  
    Cohen-Solal
    A
    ,  
    Juillière
    Y
    ,  
    Kromer
    EP
    ,  
    Benhamda
    K
    .  et al. 
    Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of a double-blind, randomized comparative trial.
    Circulation
    1998
    98
    757
    65
     PubMed
  75. Morgan
    TO
    ,  
    Anderson
    A
    ,  
    Bertram
    D
    .  
    Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril.
    Am J Hypertens
    2000
    13
    1161
    7
     PubMed
  76. Dzau
    VJ
    ,  
    Bernstein
    K
    ,  
    Celermajer
    D
    ,  
    Cohen
    J
    ,  
    Dahlöf
    B
    ,  
    Deanfield
    J
    .  et al. 
    Pathophysiologic and therapeutic importance of tissue ACE: a consensus report.
    Cardiovasc Drugs Ther
    2002
    16
    149
    60
     PubMed
  77. Pavlicević
    I
    ,  
    Kuzmanić
    M
    ,  
    Rumboldt
    M
    ,  
    Rumboldt
    Z
    .  
    Interaction between antihypertensives and NSAIDs in primary care: a controlled trial.
    Can J Clin Pharmacol
    2008
    15
    372
    82
     PubMed
  78. Pilote
    L
    ,  
    Abrahamowicz
    M
    ,  
    Rodrigues
    E
    ,  
    Eisenberg
    MJ
    ,  
    Rahme
    E
    .  
    Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect?
    Ann Intern Med
    2004
    141
    102
    12
     PubMed
  79. Remme
    WJ
    .  
    Secondary prevention of coronary artery disease and the choice of the ACE inhibitor why EUROPA and not PEACE [Editorial].
    Cardiovasc Drugs Ther
    2007
    21
    405
    7
     PubMed
  80. Shah
    AD
    ,  
    Arora
    RR
    .  
    Tissue angiotensin-converting enzyme inhibitors: are they more effective than serum angiotensin-converting enzyme inhibitors?
    Clin Cardiol
    2005
    28
    551
    5
     PubMed
  81. Lonn
    E
    ,  
    Yusuf
    S
    ,  
    Dzavik
    V
    ,  
    Doris
    C
    ,  
    Yi
    Q
    ,  
    Smith
    S
    .  et al. 
    SECURE Investigators
    Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE).
    Circulation
    2001
    103
    919
    25
     PubMed
Appendix Figure.
Literature search and selection.

IHD = ischemic heart disease; LV = left ventricular; RCT = randomized, controlled trial.

* We included 3 citations at this step after a manual reference search.

† We included 27 citations from the outcomes search and evaluated them for harms data.

‡ We included 1 citation at this step after a manual reference search.

Figure.
Meta-analysis of randomized, placebo-controlled trials of ACE inhibitors or ARBs in patients with stable ischemic heart disease and preserved left ventricular systolic function.

ACE = angiotensin-converting enzyme; ARB = angiotensin II–receptor blocker; CAMELOT = Comparison of Amlodipine vs. Enalapril to Limit Occurrences of Thrombosis; EUROPA = European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease; HOPE = Heart Outcomes Prevention Evaluation; MI = myocardial infarction; PART-2 = Prevention of Atherosclerosis with Ramipril 2; PEACE = Prevention of Events with Angiotensin Converting Enzyme Inhibition; RR = relative risk; SCAT = Simvastatin/Enalapril Coronary Atherosclerosis Trial; TRANSCEND = Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease.

Table 1.

Outcomes, Strength of Evidence, and Conclusions

Table 1.

Appendix Table.

Description of Included RCTs

Appendix Table.

Table 2.

Harms Event Rates for ACE Inhibitors

Table 2.

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

1 Comment

Alain Braillon

Public Health

December 22, 2009

Effectiveness of therapeutic reviews in search for efficiency.

Effectiveness of therapeutic reviews and search for efficiency.

For patients with stable ischemic heart disease, Baker et al finally showed that adding an Angiotensin-Converting Enzyme Inhibitor (ACEI) to standard medical therapy decrease mortality and morbidity while there was less evidence supporting a benefit of Angiotensin Receptor Blockers (ARB) therapy (1). However, I have concern for the effectiveness of this review.

For hypertension, ONTARGET is one of many studies showing that both classes give the same benefits in outcome for mortality and morbidity (2). In contrast, there are huge differences for prices: eg. in France, a daily treatment with Captopril or its generics costs 0.33 euro vs 0.67 to 0.74 euro for ARB. Prices are not related to the social value of the product: cost-effectiveness analysis (ie efficiency) seems inexistent and far beyond the capabilities of national pricing committees. Conflicts of interest in medicine are the subject of intensive and extensive debates. These debates divert us from the sad reality. The data are available to every one but very few professionals, either experts or practitioners, have concern for price. Price which is paid by the most deprived, the patient. We know what is wrong, why are we so weak that we cannot adjust our behavior and take back control.

References

1 Baker WL, Coleman CI, Kluger J, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease.Ann Intern Med. 2009;151:861-71.

2 Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, et al. Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events. N Eng J Med 2008;358:1547-59.

3 http://www.has-sante.fr/portail/upload/docs/application/pdf/2008- 10/fiche_iec_sartans_011008.pdf accessed Dec. 22, 2009

Conflict of Interest:

None declared

PDF
Not Available
Citations
Citation

Baker WL, Coleman CI, Kluger J, et al. Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II–Receptor Blockers for Ischemic Heart Disease. Ann Intern Med. 2009;151:861–871. doi: https://doi.org/10.7326/0000605-200912150-00162

Download citation file:

  • Ris (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2019

×
Permissions

Published: Ann Intern Med. 2009;151(12):861-871.

DOI: 10.7326/0000605-200912150-00162

65 Citations

Related Articles

Good evidence supports use of ACE inhibitors in stable ischemic heart disease; little evidence exists for ARBs
Annals of Internal Medicine; 152 (10): JC5-3
Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers for Treating Essential Hypertension
Annals of Internal Medicine; 148 (1): 16-29
Renin–Angiotensin System Blockade Therapy After Surgical Aortic Valve Replacement for Severe Aortic Stenosis: A Cohort Study
Annals of Internal Medicine; 161 (10): 699-710
Review: In diabetes, ACE-Is, but not ARBs, reduce mortality and major CV events compared with placebo or active treatment
Annals of Internal Medicine; 161 (4): JC2
View MoreView Less

Journal Club

Good evidence supports use of ACE inhibitors in stable ischemic heart disease; little evidence exists for ARBs
Annals of Internal Medicine; 152 (10): JC5-3
Review: In diabetes, ACE-Is, but not ARBs, reduce mortality and major CV events compared with placebo or active treatment
Annals of Internal Medicine; 161 (4): JC2
Aliskiren increased adverse events in patients with diabetes and kidney disease who were receiving ACE inhibitors or ARBs
Annals of Internal Medicine; 158 (6): JC7
Review: ACE inhibitors reduce risk for pneumonia
Annals of Internal Medicine; 157 (10): JC5-2
View MoreView Less

Related Point of Care

Stable Ischemic Heart Disease
Annals of Internal Medicine; 160 (1): ITC1-1
View MoreView Less

Related Topics

Cardiology
Coronary Heart Disease
Coronary Risk Factors
High Value Care
Hypertension

Cardiology, Coronary Heart Disease, Coronary Risk Factors, High Value Care, Hypertension.

PubMed Articles

Activity-based protein profiling of the human failing ischemic heart reveals alterations in hydrolase activities involving the endocannabinoid system.
Pharmacol Res 2019.
Transcription-independent Induction of ERBB1 through Hypoxia-inducible Factor 2A Provides Cardioprotection during Ischemia and Reperfusion.
Anesthesiology 2019.
View More

Results provided by: PubMed

CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Latest RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards and Cover

  • Personae (Cover Photo)
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×